This is a preview of subscription content, log in via an institution to check access.
Notes
The study was affiliated with, and funded by, Novartis Pharmaceuticals.
Costs included those for drug acquisition and administration, transplant procedures, radiotherapy, adverse events, follow-up, disease transformation and progression, end-of-life care, and lost productivity due to FL or death.
Reference
Eichten C, et al. Lifetime Costs for Treated Follicular Lymphoma Patients in the US. PharmacoEconomics : 17 Jul 2021. Available from: URL: http://doi.org/10.1007/s40273-021-01052-3
Rights and permissions
About this article
Cite this article
Lifetime costs of follicular lymphoma high in the USA. PharmacoEcon Outcomes News 884, 21 (2021). https://doi.org/10.1007/s40274-021-7928-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7928-0